




MS SHARMA / 34 Yrs / F / 0 Cms / 0 Kg / HR 100

Date: 23 - 12 - 2023

BP- 135/91 mmHg BLC On Netch On HR 0.05 Hz LF 20 Hz



Post R. Wave Progression in V1-V4
 TDR ARIF HUSSAIN KHAN
 MBBS PGDCC
 Wave Inversion in V3
 PMC NUMBER 023361

Name	: Ms. Sweta Sharma	Age/Sex	: 34 Yrs/ FEMALE
Ref.By	: AAKRATI LABS	Date	: 23 December 2023

RADIOGRAPH OF CHEST : PA VIEW

P.S. Suboptimal contrast factor settings creating artefacts in the region of interest leading to suboptimal evaluation. No history provided in regards to x ray done. Reporting is done with these limitations.

Metal artefacts ++

Soft tissue and bony cage are normal.

Both lungs are clear.

Both domes of diaphragm are normal in position and contour.

Hilar shadows are normal.

Mediastinum is central.

Both costo-phrenic angles are clear.

Cardio-thoracic ratio is normal with normal heart borders.

IMPRESSION:

- NO OBVIOUS ABNORMALITY.



DR. SHUBHAM SINGHAL
CONSULTANT RADIOLOGIST



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod
Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661
www.aakritilabs.com
CIN NO.: U85195RJ2004PTC019563

Dr. RAKESH SHARMA
M.S. OPTH. B. OPTH
FICLLP



Name : Mrs. SWETA SHARMA

Registration No: 71912

Age/Gender: 34 Y/Female

Registered : 23/Dec/2023 11:19AM

Patient ID : 012312230067

Analysed : 23/Dec/2023 11:43AM

BarcodeNo : 10108541

Reported : 23/Dec/2023 11:43AM

Referred By : Self

Panel : MEDI WHEEL (ARCOFEMI HEALTHCARE LTD)

OPHTHALMIC VISION TESTING		
	RIGHT EYE	LEFT EYE
UCVA	G/24	G/24
COLOURS	clear	clear
FUNDUS	wnh	wnh

	RIGHT EYE					LEFT EYE				
	SPH	CYL	AXIS	NEAR ADD	AV	SPH	CYL	AXIS	NEAR ADD	AV
PG	-0.75	-0.50	20°		6/6	-1.25				6/6
ACCEPTANCE										
DILATED										
ADVISE										

Dr. RAKESH SHARMA
M.S. OPTH. B. O
FICLLP

*** End Of Report ***

Page 1 of 1





Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod.
Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661
www.aakritilabs.com
CIN NO.: U85195RJ2004PTC019563



Name : **Mrs. SWETA SHARMA**
Age/Gender: 34 Y/Female
Patient ID : 012312230067
BarcodeNo : 10108541
Referred By : Self

Registration No: 71912
Registered : 23/Dec/2023 11:19AM
Analysed : 23/Dec/2023 01:59PM
Reported : 23/Dec/2023 02:00PM
Panel : MEDI WHEEL (ARCOFEMI
HEALTHCARE LTD)

USG: WHOLE ABDOMEN (Female)

- LIVER** : Is normal in size, shape and echogenicity.
The IHBR and hepatic radicals are not dilated.
No evidence of focal echopoor/echorich lesion seen.
Portal vein diameter and Common bile duct normal in size
- GALL BLADDER** : Is normal in size, shape and echotexture. Walls are smooth and regular with normal thickness. There is no evidence of cholelithiasis.
- PANCREAS**: Is normal in size, shape and echotexture. Pancreatic duct is not dilated.
- SPLEEN** : Is normal in size, shape and echogenicity. Spleenic hilum is not dilated.
- KIDNEYS** : Bilateral Kidneys are normal in size, shape and echotexture, corticomedullary differentiation is fair and ratio appears normal.
Pelvi calyceal system is normal. No evidence of hydronephrosis/nephrolithiasis.
- URINARY BLADDER** : Bladder walls are smooth, regular and normal thickness.
No evidence of mass or stone in bladder lumen.
- UTERUS** : Uterus is anteverted with normal in size shape & echotexture.
Uterine muscular shadows normal echopattern.
Endometrium is normal and centrally placed.
No evidence of mass lesion is seen.
- ADNEXA** : Both the ovaries are normal in size shape and echotexture.
No mass lesion/ polycystic ovarian cyst is seen.
- SPECIFIC** : No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity.
NO evidence of lymphadenopathy or mass lesion in retroperitoneum.
Visualized bowel loop appear normal. Great vessels appear normal.

IMPRESSION: Ultra Sonography findings are suggestive of: **NORMAL STUDY.**

*** End Of Report ***

Page 2 of 2



Dr. Neera Mehta
M.B.B.S., D.M.R.D.



PATIENT NAME : SWETA SHARMA **REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0251WL001938 PATIENT ID : SWETF231289251 CLIENT PATIENT ID: 012312230067 ABHA NO :	AGE/SEX : 34 Years Female DRAWN : 23/12/2023 11:19:00 RECEIVED : 23/12/2023 11:31:26 REPORTED : 25/12/2023 16:39:46
--	--	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY - CBC

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

BLOOD COUNTS,EDTA WHOLE BLOOD

HEMOGLOBIN (HB) <small>METHOD : CYANIDE FREE DETERMINATION</small>	12.5	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT <small>METHOD : ELECTRICAL IMPEDANCE</small>	4.19	3.8 - 4.8	mil/ μ L
WHITE BLOOD CELL (WBC) COUNT <small>METHOD : ELECTRICAL IMPEDANCE</small>	7.30	4.0 - 10.0	thou/ μ L
PLATELET COUNT <small>METHOD : ELECTRONIC IMPEDANCE</small>	216	150 - 410	thou/ μ L

RBC AND PLATELET INDICES

HEMATOCRIT (PCV) <small>METHOD : CALCULATED PARAMETER</small>	37.7	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV) <small>METHOD : CALCULATED PARAMETER</small>	90.0	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) <small>METHOD : CALCULATED PARAMETER</small>	29.8	27.0 - 32.0	Pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) <small>METHOD : CALCULATED PARAMETER</small>	33.1	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) <small>METHOD : CALCULATED PARAMETER</small>	12.8	11.6 - 14.0	%
MENTZER INDEX	21.5		
MEAN PLATELET VOLUME (MPV) <small>METHOD : CALCULATED PARAMETER</small>	9.7	6.8 - 10.9	fL

WBC DIFFERENTIAL COUNT

NEUTROPHILS <small>METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY</small>	75	40 - 80	%
LYMPHOCYTES <small>METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY</small>	19 Low	20 - 40	%
MONOCYTES	05	2 - 10	%


Dr. Akansha Jain
Consultant Pathologist





PATIENT NAME : SWETA SHARMA REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0251WL001938 PATIENT ID : SWETF231289251 CLIENT PATIENT ID: 012312230067 ABHA NO :	AGE/SEX : 34 Years Female DRAWN : 23/12/2023 11:19:00 RECEIVED : 23/12/2023 11:31:26 REPORTED : 25/12/2023 16:39:46
---	--	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY				
EOSINOPHILS	01	1 - 6		%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY				
BASOPHILS	00	0 - 2		%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY				
ABSOLUTE NEUTROPHIL COUNT	5.48	2.0 - 7.0		thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT	1.39	1.0 - 3.0		thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT	0.36	0.2 - 1.0		thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT	0.07	0.02 - 0.50		thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10		thou/ μ L
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	3.9			

Interpretation(s)
 BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.
 RBC AND PLATELET INDICES-Mentzer Index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.
 WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.
 [Reference to - The diagnostic and predictive role ofNLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504
 This ratio element is a calculated parameter and out ofNABL scope.

Dr. Akansha Jain
Consultant Pathologist



View Details

View Report

PERFORMED AT :
 Agilus Diagnostics Ltd.
 C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
 Jaipur, 302015
 Rajasthan, India





PATIENT NAME : SWETA SHARMA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138404
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0251WL001938
PATIENT ID : SWETF231289251
CLIENT PATIENT ID: 012312230067
ABHA NO :

AGE/SEX : 34 Years Female
DRAWN : 23/12/2023 11:19:00
RECEIVED : 23/12/2023 11:31:26
REPORTED : 25/12/2023 16:39:46

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C	4.8	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
-------	-----	--	---

METHOD : HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG)	91.1	< 116.0	mg/dL
--------------------------------	------	---------	-------

METHOD : CALCULATED PARAMETER

Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



PATIENT NAME : SWETA SHARMA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0251WL001938

PATIENT ID : SWETF231289251

CLIENT PATIENT ID: 012312230067

ABHA NO :

AGE/SEX : 34 Years Female

DRAWN : 23/12/2023 11:19:00

RECEIVED : 23/12/2023 11:31:26

REPORTED : 25/12/2023 16:39:46

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD

E.S.R 20 0 - 20 mm at 1 hr

METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)*

Interpretation(s)

GLYCOSYLATED HEMOGLOBIN(HbA1c), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.
- 3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.

- 1. eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.
- 2. eAG gives an evaluation of blood glucose levels for the last couple of months.
- 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c + 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2. Vitamin C & E are reported to falsely lower test results (possibly by inhibiting glycation of hemoglobin).
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD- TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitis, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy ESR in first trimester is 0-48 mm/hr (52 if anemic) and in second trimester (0-70 mm/hr (95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs (vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Polikilocytosis, (Sickle Cells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE :

- 1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition;
- 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin;
- 3. The reference for the adult reference range is "Practical Haematology" by Dacie and Lewis, 10th edition.

Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Aglus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000005853595

PATIENT NAME : SWETA SHARMA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138404
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0251WL001938
PATIENT ID : SWETF231289251
CLIENT PATIENT ID: 012312230067
ABHA NO :

AGE/SEX : 34 Years Female
DRAWN : 23/12/2023 11:19:00
RECEIVED : 23/12/2023 11:31:26
REPORTED : 25/12/2023 16:39:46

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40 FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE AB
METHOD : TUBE AGGLUTINATION
RH TYPE POSITIVE
METHOD : TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A, B, O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain
Consultant Pathologist

Page 5 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000095853595



PATIENT NAME : SWETA SHARMA **REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0251WL001938 PATIENT ID : SWETF231289251 CLIENT PATIENT ID: 012312230067 ABHA NO :	AGE/SEX : 34 Years Female DRAWN : 23/12/2023 11:19:00 RECEIVED : 23/12/2023 11:31:26 REPORTED : 25/12/2023 16:39:46
--	--	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING,FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)	100 High	74 - 99	mg/dL
METHOD : GLUCOSE OXIDASE			

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)	83	70 - 140	mg/dL
METHOD : GLUCOSE OXIDASE			

LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL	198	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD : CHOLESTEROL OXIDASE			

TRIGLYCERIDES	57	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD : LIPASE/GPO-PAP NO CORRECTION			

HDL CHOLESTEROL	44	< 40 Low >/=60 High	mg/dL
METHOD : DIRECT CLEARANCE METHOD			

CHOLESTEROL LDL	143 High	< 100 Optimal 100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
------------------------	-----------------	--	-------

NON HDL CHOLESTEROL	154 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
METHOD : CALCULATED PARAMETER			

Dr. Akansha Jain
Consultant Pathologist



[View Details](#) [View Report](#)

PERFORMED AT :
Agius Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India





PATIENT NAME : SWETA SHARMA		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0251WL001938 PATIENT ID : SWETF231289251 CLIENT PATIENT ID: 012312230067 ABHA NO : :	AGE/SEX : 34 Years Female DRAWN : 23/12/2023 11:19:00 RECEIVED : 23/12/2023 11:31:26 REPORTED : 25/12/2023 16:39:46	

Test Report Status	Final	Results	Biological Reference Interval	Units
VERY LOW DENSITY LIPOPROTEIN CHOL/HDL RATIO		11.4 4.5 High	</= 30.0 3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	mg/dL
LDL/HDL RATIO		3.3 High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category	
Extreme risk group	A. CAD with > 1 feature of high risk group B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors
Low Risk	0-1 major ASCVD risk factors
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors	
1. Age > or = 45 years in males and > or = 55 years in females	3. Current Cigarette smoking or tobacco use
2. Family history of premature ASCVD	4. High blood pressure
5. Low HDL	

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	< 80 (Optional goal <OR = 60)	>OR = 50	>OR = 80

Dr. Akansha Jain
Consultant Pathologist



View Details

View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



PATIENT NAME : SWETA SHARMA **REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0251WL001938 PATIENT ID : SWETF231289251 CLIENT PATIENT ID : 012312230067 ABHA NO :	AGE/SEX : 34 Years Female DRAWN : 23/12/2023 11:19:00 RECEIVED : 23/12/2023 11:31:26 REPORTED : 25/12/2023 16:39:46
--	---	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Extreme Risk Group Category B	<OR = 30	<OR = 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology. 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL METHOD : DIAZO WITH SULPHANILIC ACID	0.59	0 - 1	mg/dL
BILIRUBIN, DIRECT METHOD : DIAZO WITH SULPHANILIC ACID	0.18	0.00 - 0.25	mg/dL
BILIRUBIN, INDIRECT METHOD : CALCULATED PARAMETER	0.41	0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD : BIURET REACTION, END POINT	8.7 High	6.4 - 8.2	g/dL
ALBUMIN METHOD : BROMOCRESOL GREEN	4.8 High	3.8 - 4.4	g/dL
GLOBULIN METHOD : CALCULATED PARAMETER	3.9	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED PARAMETER	1.2	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD : TRIS BUFFER NO PSP IFCC / SFBC 37° C	37 High	0 - 31	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : TRIS BUFFER NO PSP IFCC / SFBC 37° C	27	0 - 31	U/L
ALKALINE PHOSPHATASE METHOD : AMP OPTIMISED TO IFCC 37° C	61	39 - 117	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : GAMMA GLUTAMYL-3-CARBOXY-4-NITROANILIDE (IFCC) 37° C	21	7 - 32	U/L
LACTATE DEHYDROGENASE	420	230 - 460	U/L

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN METHOD : UREASE KINETIC	8	5.0 - 18.0	mg/dL
---	---	------------	-------



Dr. Akansha Jain
Consultant Pathologist



[View Details](#)

[View Report](#)

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000095853595



HC-5726

PATIENT NAME : SWETA SHARMA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138404
 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
 DELHI
 NEW DELHI 110030
 8800465156

ACCESSION NO : 0251WL001938
 PATIENT ID : SWETF231289251
 CLIENT PATIENT ID: 012312230067
 ABHA NO :

AGE/SEX : 34 Years Female
 DRAWN : 23/12/2023 11:19:00
 RECEIVED : 23/12/2023 11:31:26
 REPORTED : 25/12/2023 16:39:46

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CREATININE, SERUM

CREATININE	0.81	0.6 - 1.2	mg/dL
METHOD : ALKALINE PICRATE NO DEPROTEINIZATION			

BUN/CREAT RATIO

BUN/CREAT RATIO	9.88		
METHOD : CALCULATED PARAMETER			

URIC ACID, SERUM

URIC ACID	3.7	2.4 - 5.7	mg/dL
METHOD : URICASE PEROXIDASE WITH ASCORBATE OXIDASE			

TOTAL PROTEIN, SERUM

TOTAL PROTEIN	8.7 High	6.4 - 8.3	g/dL
METHOD : BIURET REACTION, END POINT			

ALBUMIN, SERUM

ALBUMIN	4.8 High	3.8 - 4.4	g/dL
METHOD : BROMOCRESOL GREEN			

GLOBULIN

GLOBULIN	3.9	2.0 - 4.1	g/dL
----------	-----	-----------	------

ELECTROLYTES (NA/K/CL), SERUM

Dr. Akansha Jain
 Consultant Pathologist

Page 9 Of 18



View Details

View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
 C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
 Jaipur, 302015
 Rajasthan, India



Patient Ref. No. 775000095853595

PATIENT NAME : SWETA SHARMA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138404
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0251WL001938
PATIENT ID : SWETF231289251
CLIENT PATIENT ID: 012312230067
ABHA NO :

AGE/SEX : 34 Years Female
DRAWN : 23/12/2023 11:19:00
RECEIVED : 23/12/2023 11:31:26
REPORTED : 25/12/2023 16:39:46

Test Report Status	Final	Results	Biological Reference Interval	Units
SODIUM, SERUM		139.8	137 - 145	mmol/L
METHOD : ION-SELECTIVE ELECTRODE				
POTASSIUM, SERUM		4.71	3.6 - 5.0	mmol/L
METHOD : ION-SELECTIVE ELECTRODE				
CHLORIDE, SERUM		100.6	98 - 107	mmol/L
METHOD : ION-SELECTIVE ELECTRODE				

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in: CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenal insufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessive sweating, severe vomiting or diarrhea), diabetes mellitus, diabetes insipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, high-dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO ₃ ⁻), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemia, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in: Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia), Drugs- insulin, ethanol, propranolol, sulfonureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.



Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Aglus Diagnostics Ltd.
 C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
 Jaipur, 302015
 Rajasthan, India



Patient Ref. No. 775000095853595

PATIENT NAME : SWETA SHARMA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138404
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0251WL001938
PATIENT ID : SWETF231289251
CLIENT PATIENT ID: 012312230067
ABHA NO :

AGE/SEX : 34 Years Female
DRAWN : 23/12/2023 11:19:00
RECEIVED : 23/12/2023 11:31:26
REPORTED : 25/12/2023 16:39:46

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycaemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycaemia, Increased insulin response & sensitivity etc. Additional test HbA1c

LIVERFUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease. Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or perniciou anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatase, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodialysis, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

BLOOD UREA NITROGEN (BUN), SERUM- Causes of **Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM- Higher than normal level may be due to:

- Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscular Dystrophy

URIC ACID, SERUM- Causes of **Increased** levels: Dietary (High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome. Causes of **decreased** levels: Low Zinc intake, COP, Multiple Sclerosis

TOTAL PROTEIN, SERUM- is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM- Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. **Low blood albumin levels (hypoalbuminemia) can be caused by:** Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodialysis, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.



Dr. Akansha Jain
Consultant Pathologist



[View Details](#) [View Report](#)

PERFORMED AT :
 Agilus Diagnostics Ltd.
 C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
 Jaipur, 302015
 Rajasthan, India





HC-5726

PATIENT NAME : SWETA SHARMA REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0251WL001938 PATIENT ID : SWETF231289251 CLIENT PATIENT ID : 012312230067 ABHA NO :	AGE/SEX : 34 Years Female DRAWN : 23/12/2023 11:19:00 RECEIVED : 23/12/2023 11:31:26 REPORTED : 25/12/2023 16:39:46
--	---	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR	PALE YELLOW
METHOD : GROSS EXAMINATION	
APPEARANCE	CLEAR
METHOD : GROSS EXAMINATION	

CHEMICAL EXAMINATION, URINE

PH	6.5	4.7 - 7.5
METHOD : DOUBLE INDICATOR PRINCIPLE		
SPECIFIC GRAVITY	1.010	1.003 - 1.035
METHOD : IONIC CONCENTRATION METHOD		
PROTEIN	TRACE	NEGATIVE
METHOD : PROTEIN ERROR OF INDICATORS WITH REFLECTANCE		
GLUCOSE	NOT DETECTED	NEGATIVE
METHOD : GLUCOSE OXIDASE PEROXIDASE / BENEDICTS		
KETONES	NOT DETECTED	NOT DETECTED
METHOD : SODIUM NITROPRUSSIDE REACTION		
BLOOD	NOT DETECTED	NEGATIVE
METHOD : PEROXIDASE ANTI PEROXIDASE		
BILIRUBIN	NOT DETECTED	NOT DETECTED
METHOD : DIPSTICK		
UROBILINOGEN	NORMAL	NORMAL
METHOD : EHRlich REACTION REFLECTANCE		
NITRITE	NOT DETECTED	NOT DETECTED
METHOD : NITRATE TO NITRITE CONVERSION METHOD		
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION			
PUS CELL (WBC'S)	1-2	0-5	/HPF
METHOD : DIPSTICK, MICROSCOPY			

Dr. Akansha Jain
Consultant Pathologist



[View Details](#)

[View Report](#)

PERFORMED AT :

Agilus Diagnostics Ltd.
 C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
 Jaipur, 302015
 Rajasthan, India





HC-5726

PATIENT NAME : SWETA SHARMA**REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000138404
 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
 F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
 DELHI
 NEW DELHI 110030
 8800465156

ACCESSION NO : **0251WL001938**
 PATIENT ID : SWETF231289251
 CLIENT PATIENT ID: 012312230067
 ABHA NO :

AGE/SEX : 34 Years Female
 DRAWN : 23/12/2023 11:19:00
 RECEIVED : 23/12/2023 11:31:26
 REPORTED : 25/12/2023 16:39:46

Test Report Status	Final	Results	Biological Reference Interval	Units
EPITHELIAL CELLS		2-3	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION				
CASTS		NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
CRYSTALS		NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
BACTERIA		NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION				
YEAST		NOT DETECTED	NOT DETECTED	

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases

Dr. Akansha Jain
 Consultant Pathologist

Page 13 Of 18



View Details

View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
 C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
 Jaipur, 302015
 Rajasthan, India



Patient Ref. No. 77500005853595



PATIENT NAME : SWETA SHARMA **REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0251WL001938	AGE/SEX : 34 Years Female
	PATIENT ID : SWETF231289251	DRAWN : 23/12/2023 11:19:00
	CLIENT PATIENT ID: 012312230067	RECEIVED : 23/12/2023 11:31:26
	ABHA NO :	REPORTED : 25/12/2023 16:39:46

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infection when present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Akansha Jain
Consultant Pathologist



[View Details](#)



[View Report](#)

PERFORMED AT :
Aglus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India





PATIENT NAME : SWETA SHARMA **REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0251WL001938	AGE/SEX : 34 Years Female
	PATIENT ID : SWETF231289251	DRAWN : 23/12/2023 11:19:00
	CLIENT PATIENT ID: 012312230067	RECEIVED : 23/12/2023 11:31:26
	ABHA NO :	REPORTED : 25/12/2023 16:39:46

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD SAMPLE NOT RECEIVED

Dr. Akansha Jain
Consultant Pathologist



[View Details](#)

[View Report](#)

PERFORMED AT :
 Agilus Diagnostics Ltd.
 C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
 Jaipur, 302015
 Rajasthan, India





PATIENT NAME : SWETA SHARMA		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0251WL001938	AGE/SEX : 34 Years Female	DRAWN : 23/12/2023 11:19:00
	PATIENT ID : SWETF231289251	RECEIVED : 23/12/2023 11:31:26	REPORTED : 25/12/2023 16:39:46
	CLIENT PATIENT ID: 012312230067		
	ABHA NO :		

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION,STOOL

COLOUR SAMPLE NOT RECEIVED

METHOD : GROSS EXAMINATION

Dr. Abhishek Sharma
Consultant Microbiologist



[View Details](#)

[View Report](#)

PERFORMED AT :
 Agilus Diagnostics Ltd.
 C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
 Jaipur, 302015
 Rajasthan, India



Patient Ref. No. 775000095853595



HC-5726

PATIENT NAME : SWETA SHARMA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000138404

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST
DELHI
NEW DELHI 110030
8800465156

ACCESSION NO : 0251WL001938

PATIENT ID : SWETF231289251

CLIENT PATIENT ID: 012312230067

ABHA NO :

AGE/SEX : 34 Years Female

DRAWN : 23/12/2023 11:19:00

RECEIVED : 23/12/2023 11:31:26

REPORTED : 25/12/2023 16:39:46

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40 FEMALE

THYROID PANEL, SERUM

T3	105.94	60.0 - 181.0	ng/dL
METHOD : CHEMILUMINESCENCE			
T4	7.00	4.5 - 10.9	µg/dL
METHOD : CHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	2.362	0.550 - 4.780	µIU/mL
METHOD : CHEMILUMINESCENCE			

Interpretation(s)

Triiodothyronine T3 , Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level

is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most

of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically

active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1) Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Dr. Akansha Jain
Consultant Pathologist

Page 17 Of 18



View Details

View Report

PERFORMED AT :

Aglus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India

Patient Ref. No. 77500009583595



HC-5726

PATIENT NAME : SWETA SHARMA **REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000138404 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0251WL001938 PATIENT ID : SWETF231289251 CLIENT PATIENT ID : 012312230067 ABHA NO :	AGE/SEX : 34 Years Female DRAWN : 23/12/2023 11:19:00 RECEIVED : 23/12/2023 11:31:26 REPORTED : 25/12/2023 16:39:46
--	--	--

Test Report Status Final	Results	Biological Reference Interval	Units
--	----------------	--------------------------------------	--------------

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011.
NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

****End Of Report****
Please visit www.agilusdiagnostics.com for related Test Information for this accession


Dr. Akansha Jain
Consultant Pathologist



PERFORMED AT :
Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India

